SOURCE: Applied DNA Sciences Inc.
STONY BROOK, NY--(Marketwire - Nov 29, 2012) - Applied DNA Sciences, Inc. (OTCBB: APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that it has entered into a Securities Purchase Agreement (the "Agreement") with an institutional accredited investor, Crede CG II, Ltd., to provide a minimum of $7.5 Million in financing. At the initial closing, the Company received gross proceeds of $2,000,000 in exchange for restricted common stock priced at $0.186/share.
Pursuant to the Agreement, the investor is obligated to invest an additional $5,500,000 in convertible preferred stock of the Company on the date a registration statement providing for the resale of the securities issued is declared effective by the Securities and Exchange Commission ("Second Closing"). This closing will be done at $1,000 per share of preferred stock with a conversion price the lesser of market or $0.186/share. The investor is limited to 9.9% ownership at any given point in time. The investor is in a "passive" position and will not occupy a Board position. The preferred stock will generally be non-voting with no dividends and will rank senior to the common stock on liquidation. The preferred stock is subject to conversion into common stock at the Company's option following effectiveness of the registration statement and automatically converts after one year.
Warrants issued as a part of this financing could contribute up to an additional $9.0 million in funds to the company if exercised for cash. Warrants would be exercised at a strike price equal to $.2232 per share which is a 20% premium to the original purchase price of $0.186/share. The Company intends to file a registration statement covering the common stock and common stock underlying warrants and preferred stock.
More detailed information on this financing can be found in the Form 8-K filed with the SEC.
APDN intends to use the additional capital to take advantage of recent developments in its business verticals in recent months, including in electronics, textiles, and anti-theft products. The company has already expanded its plant and staff in order to accommodate this progression, and aims to continue and broaden that expansion.
Dr. James A. Hayward, President and CEO of Applied DNA Sciences, said, "This is a crucial stage in the development of Applied DNA Sciences. Access to this capital enhances our capacity to respond to growth opportunities, including those subsequent to the US military mandate that electronic suppliers mark their products supplied to the Defense Logistics Agency with our SigNature DNA®."
About Applied DNA Sciences
APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.
The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.